glucagon

Boehringer Ingelheim ADA2026 BI

Biotech

ADA: Tolerability questions linger for Boehringer's obesity drug

A deeper dive into survodutide’s performance could undercut the GLP-1/glucagon drug’s competitiveness on raw weight loss and tolerability.

Fraiser Kansteiner Jun 8, 2026 4:30am

Lilly ADA

ADA: Lilly offers deeper glimpse into triple-G obesity candidate

Jun 6, 2026 3:28pm

Eli Lilly Lilly

Lilly's $1.2B deal for Hanmi GLP-2 drug for short bowel syndrome

Jun 1, 2026 3:52am

Diabetes obesity weight loss

Lilly triple-G bet sees 16.8% weight loss in ph. 3 diabetes test

Mar 19, 2026 6:45am

Graphic images of white and black puzzle pieces connecting seamlessly

Eli Lilly taps Camurus' tech to advance long-acting obesity meds

Jun 3, 2025 5:04pm